Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20254Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Pappas, G. | en |
| dc.contributor.author | Akritidis, N. | en |
| dc.contributor.author | Christou, L. | en |
| dc.date.accessioned | 2015-11-24T19:05:51Z | - |
| dc.date.available | 2015-11-24T19:05:51Z | - |
| dc.identifier.issn | 1744-8336 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20254 | - |
| dc.rights | Default Licence | - |
| dc.subject | Anti-Bacterial Agents/*therapeutic use | en |
| dc.subject | Brucellosis/complications/*drug therapy | en |
| dc.subject | Ceftriaxone/therapeutic use | en |
| dc.subject | Central Nervous System Bacterial Infections/*drug therapy/etiology | en |
| dc.subject | Doxycycline/*therapeutic use | en |
| dc.subject | Drug Administration Schedule | en |
| dc.subject | Humans | en |
| dc.subject | Rifampin/therapeutic use | en |
| dc.subject | Streptomycin/therapeutic use | en |
| dc.title | Treatment of neurobrucellosis: what is known and what remains to be answered | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1586/14787210.5.6.983 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/18039082 | - |
| heal.identifier.secondary | http://www.expert-reviews.com/doi/abs/10.1586/14787210.5.6.983 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2007 | - |
| heal.abstract | Neurological involvement is one of the most perplexing and diverse presentation complications of brucellosis, a worldwide prevalent zoonosis. This review presents the current knowledge available from medical literature and discusses the shortcomings of the existing data. A proposed regimen should include doxycycline and rifampicin and, with the benefit of doubt, ceftriaxone, since its high concentration in the cerebrospinal fluid may offer significant efficacy against the pathogen. Corticosteroids have been used in specialized situations. The use of streptomycin is discouraged owing to its questionable ability to penetrate into the cerebrospinal fluid and its potential neurotoxicity that may perplex the clinical presentation. Treatment duration should be individualized in the absence of an adequate cut-off index. | en |
| heal.journalName | Expert Rev Anti Infect Ther | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
